J&J and Bayer's Xarelto proves its worth across PAD subgroups in 2 new analyses

Johnson & Johnson and Bayer’s wide-spanning VOYAGER PAD study continues to be a gold mine for proving its Xarelto’s worth in several subsets of patients with peripheral artery disease (PAD).

New analyses that J&J presented at this year’s American Heart Association (AHA)’s Scientific Sessions confirm the blood thinner’s benefits in patients classified as “fragile” and those with comorbid coronary artery diseases (CAD)